Yasuko Iwakiri

List of Publications by Year
in descending order

68	4,340	109321 35	118850 62
papers	citations	h-index	g-index

97	97	97	5353
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. Journal of Controlled Release, 2022, 341, 457-474.	9.9	8
2	Covidâ€19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. Hepatology Communications, 2022, 6, 255-269.	4.3	41
3	Inhibition of high-fat dietâ€“induced obesity via reduction of ER-resident protein Nogo occurs through multiple mechanisms. Journal of Biological Chemistry, 2022, 298, 101561.	3.4	7
4	Hepatic lymphatic vascular system in health and disease. Journal of Hepatology, 2022, 77, 206-218.	3.7	19
5	Enhanced Meningeal Lymphatic Drainage Ameliorates Neuroinflammation and Hepatic Encephalopathy in Cirrhotic Rats. Gastroenterology, 2021, 160, 1315-1329.e13.	1.3	45
6	Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 663-664.	4.5	0
7	Single-Cell Transcriptomics Reveals Zone-Specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1139-1161.	4.5	91
8	Pathological characteristics of liver sinusoidal thrombosis in COVIDâ€19 patients: A series of 43 cases. Hepatology Research, 2021, 51, 1000-1006.	3.4	24
9	Alcohol-induced Hsp90 acetylation is a novel driver of liver sinusoidal endothelial dysfunction and alcohol-related liver disease. Journal of Hepatology, 2021, 75, 377-386.	3.7	31
10	Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy. JHEP Reports, 2021, 3, 100316.	4.9	61
11	Obituary for Roberto J. Groszmannâ€”The Father of Portal Hypertension. Hepatology, 2021, 74, 1724-1726.	7.3	0
12	Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy. Journal of Hepatology, 2021, 75, 647-658.	3.7	67
13	Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity. Journal of Hepatology, 2020, 73, 1482-1495.	3.7	24
14	Endothelial Leukocyte Cellâ€“Derived Chemotaxin 2/Tyrosine Kinase With Immunoglobulinâ€Like and Epidermal Growth Factorâ€“Like Domains 1 Signaling in Liver Fibrosis. Hepatology, 2020, 72, 347-349.	7.3	6
15	The lymphatic system in alcohol-associated liver disease. Clinical and Molecular Hepatology, 2020, 26, 633-638.	8.9	3
16	Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation. American Journal of Physiology - Renal Physiology, 2019, 317, G387-G397.	3.4	25
17	Poly(amine-co-ester) nanoparticles for effective Nogo-B knockdown in the liver. Journal of Controlled Release, 2019, 304, 259-267.	9.9	23
18	O-GlcNAc transferase suppresses necroptosis and liver fibrosis. JCI Insight, 2019, 4, .	5.0	60

#	Article	IF	Citations
19	Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions. Drug Delivery, 2018, 25, 1055-1065.	5.7	10
20	Is miRâ€21 a potent target for liver fibrosis?. Hepatology, 2018, 67, 2082-2084.	7.3	9
21	The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatology International, 2018, 12, 1-10.	4.2	81
22	Biology of portal hypertension. Hepatology International, 2018, 12, 11-23.	4.2	67
23	Integrated analysis of microRNA and mRNA expression profiles in splenomegaly induced by non-cirrhotic portal hypertension in rats. Scientific Reports, 2018, 8, 17983.	3.3	3
24	Lymphatics in the liver. Current Opinion in Immunology, 2018, 53, 137-142.	5.5	41
25	An endoplasmic reticulum protein, Nogoâ€B, facilitates alcoholic liver disease through regulation of kupffer cell polarization. Hepatology, 2017, 65, 1720-1734.	7.3	68
26	Reply. Hepatology, 2017, 65, 2134-2134.	7.3	0
27	Alcohol and calcium make a potent cocktail. Journal of Physiology, 2017, 595, 3109-3110.	2.9	1
28	Reply. Hepatology, 2017, 66, 1702-1703.	7.3	0
29	Novel application and serial evaluation of tissue-engineered portal vein grafts in a murine model. Regenerative Medicine, 2017, 12, 929-938.	1.7	4
30	Comparative efficacy and safety of antibody induction therapy for the treatment of kidney: a network meta-analysis. Oncotarget, 2017, 8, 66426-66437.	1.8	1
31	The lymphatic system: A new frontier in hepatology. Hepatology, 2016, 64, 706-707.	7.3	21
32	The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis. Cellular and Molecular Gastroenterology and Hepatology, 2016, 2, 733-749.	4.5	97
33	Cellular distribution of injected PLGA-nanoparticles in the liver. Nanomedicine: Nanotechnology, Biology, and Medicine, 2016, 12, 1365-1374.	3.3	103
34	Pigment Epithelium-Derived Factor (PEDF) Inhibits Wnt/Î²-catenin Signaling in the Liver. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 535-549.e14.	4.5	32
35	Nitric oxide in liver fibrosis: The role of inducible nitric oxide synthase. Clinical and Molecular Hepatology, 2015, 21, 319.	8.9	84
36	Nitric oxide in liver diseases. Trends in Pharmacological Sciences, 2015, 36, 524-536.	8.7	193

#	Article	IF	Citations
37	Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. Journal of Hepatology, 2015, 62, 325-331.	3.7	65
38	Can hypersplenism secondary to portal hypertension be treated by non-selective beta blockers?. Hepatology International, 2015, 9, 337-338.	4.2	2
39	Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a. FASEB Journal, 2015, 29, 3436-3445.	0.5	50
40	Hepatic congestion leads to fibrosis: Findings in a newly developed murine model. Hepatology, 2015, 61, 428-430.	7.3	6
41	Development of Small Diameter Nanofiber Tissue Engineered Arterial Grafts. PLoS ONE, 2015, 10, e0120328.	2.5	56
42	Pathophysiology of Portal Hypertension. Clinics in Liver Disease, 2014, 18, 281-291.	2.1	208
43	Reticulon 4 Is Necessary for Endoplasmic Reticulum Tubulation, STIM1-Orai1 Coupling, and Store-operated Calcium Entry. Journal of Biological Chemistry, 2014, 289, 9380-9395.	3.4	62
44	Vascular pathobiology in chronic liver disease and cirrhosis â€“ Current status and future directions. Journal of Hepatology, 2014, 61, 912-924.	3.7	246
45	Pathophysiology of Portal Hypertension. , 2014, , 3-14.		4
46	Absence of Nogo-B (Reticulon 4B) Facilitates Hepatic Stellate Cell Apoptosis and Diminishes Hepatic Fibrosis in Mice. American Journal of Pathology, 2013, 182, 786-795.	3.8	24
47	Reticulon 4B (Nogo-B) facilitates hepatocyte proliferation and liver regeneration in mice. Hepatology, 2013, 57, 1992-2003.	7.3	31
48	The lymphatic vascular system in liver diseases: its role in ascites formation. Clinical and Molecular Hepatology, 2013, 19, 99.	8.9	70
49	A role of miR-33 for cell cycle progression and cell proliferation. Cell Cycle, 2012, 11, 1057-1057.	2.6	14
50	Proteomic Identification of S-Nitrosylated Golgi Proteins: New Insights into Endothelial Cell Regulation by eNOS-Derived NO. PLoS ONE, 2012, 7, e31564.	2.5	25
51	Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver International, 2012, 32, 199-213.	3.9	156
52	Intestinal and plasma VEGF levels in cirrhosis: the role of portal pressure. Journal of Cellular and Molecular Medicine, 2012, 16, 1125-1133.	3.6	40
53	Pigment Epithelium-Derived Factor Regulates Early Pancreatic Fibrotic Responses and Suppresses the Profibrotic Cytokine Thrombospondin-1. American Journal of Pathology, 2011, 179, 2990-2999.	3.8	23
54	S-nitrosylation of proteins: A new insight into endothelial cell function regulated by eNOS-derived NO. Nitric Oxide - Biology and Chemistry, 2011, 25, 95-101.	2.7	31

#	Article	IF	Citations
55	Reticulon 4B (Nogo-B) is a novel regulator of hepatic fibrosis. Hepatology, 2011, 53, 1306-1315.	7.3	52
56	The Systemic and Splanchnic Circulations. , 2011, , 305-321.		2
57	The Molecules. Journal of Clinical Gastroenterology, 2007, 41, S288-S294.	2.2	69
58	Vascular endothelial dysfunction in cirrhosis. Journal of Hepatology, 2007, 46, 927-934.	3.7	273
59	Increased neuronal nitric oxide synthase interaction with soluble guanylate cyclase contributes to the splanchnic arterial vasodilation in portal hypertensive rats. Hepatology Research, 2007, 37, 58-67.	3.4	18
60	Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric oxide in cirrhotic rat livers. Journal of Hepatology, 2006, 44, 886-893.	3.7	47
61	The Hyperdynamic Circulation of Chronic Liver Diseases: From the Patient to the Molecule. Hepatology, 2006, 43, S121-S131.	7.3	523
62	Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. American Journal of Physiology - Renal Physiology, 2006, 290, G980-G987.	3.4	176
63	Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19777-19782.	7.1	232
64	Targeting of Endothelial Nitric-oxide Synthase to the Cytoplasmic Face of the Golgi Complex or Plasma Membrane Regulates Akt- Versus Calcium-dependent Mechanisms for Nitric Oxide Release. Journal of Biological Chemistry, 2004, 279, 30349-30357.	3.4	119
65	Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology, 2003, 125, 1452-1461.	1.3	79
66	A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. Journal of Hepatology, 2003, 39, 940-946.	3.7	75
67	Mice with targeted deletion of eNOS develop hyperdynamic circulation associated with portal hypertension. American Journal of Physiology - Renal Physiology, 2002, 283, G1074-G1081.	3.4	77
68	Phosphorylation of eNOS initiates excessive NO production in early phases of portal hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H2084-H2090.	3.2	75